In8bio, INC 10-Q quarterly reports

IN8bio, Inc. filed its Form 10-Q for the quarter ended March 31, 2026, reporting a net loss of $5.1 million and highlighting substantial doubt about its ability to continue as a going concern.

IN8bio reports continued net losses and a dwindling cash position, raising substantial doubt about its ability to continue as a going concern, despite positive clinical data for INB-100 and INB-200.

IN8bio, a clinical-stage biopharmaceutical company, reported reduced net losses and operating expenses in Q2 2025, while advancing its gamma-delta T cell product candidates despite ongoing going concern doubts.

IN8BIO reports a net loss for Q1 2025 and expresses substantial doubt about its ability to continue as a going concern, while focusing on pipeline prioritization and cost management.

IN8bio announced a pipeline prioritization and workforce reduction in September 2024, focusing on INB-100 development and suspending INB-400 trials.

IN8bio, a clinical-stage biopharmaceutical company, released its 10-Q filing for the quarter ended June 30, 2024, detailing financial results and providing updates on its clinical programs and financial position.

IN8bio's first quarter 2024 results show a net loss of $8.6 million and highlight substantial doubt about the company's ability to continue as a going concern.